Repurposed asthma drug reverses diabetes in mouse study

02/11/2013 | Genetic Engineering & Biotechnology News

Amlexanox, an off-patent asthma drug, reversed obesity, diabetes and fatty liver disease in mice, according to a study published in Nature Medicine. The drug appears to inhibit the IKK(epsilon) and TBK1 genes, which might allow the metabolic system to burn more energy, University of Michigan Life Sciences Institute researcher Alan Saltiel said. Researchers plan to test the drug in clinical trials and are working on optimized formulas.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
In house Compliance Officer
Confidential
Pompano Beach, FL